Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
Frank A. Sinicrope(Mayo Clinic), Jeffrey A. Meyerhardt(CancerCare), Walter R. Peters(Baylor University Medical Center), Anke Reinacher‐Schick(Ruhr University Bochum), Samara L. Potter(Nationwide Children's Hospital), Khalid Matin(Virginia Cancer Institute), Deirdre Jill Cohen(Icahn School of Medicine at Mount Sinai), Dirk Arnold(Asklepios Klinik Altona), Dennis Hsu(Memorial Sloan Kettering Cancer Center), Fang‐Shu Ou(Mayo Clinic), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Ardaman Shergill(University of Chicago), Robert J. Behrens(Iowa Oncology Research Association), Clare A. Gatten(Mayo Clinic), Christopher H. Lieu(University of Colorado Denver), Wendy L. Frankel(The Ohio State University Wexner Medical Center), Tyler Zemla(Mayo Clinic)
Cited by 47
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k